Modulation of Prepulse Inhibition (PPI) of the Acoustic Startle Reflex by Periadolescent Antipsychotic and Antidepressant Drug Treatment in Offspring Born to PolyI:C-Treated and Control (CON) Mothers. Inhibition of the startle reflex to a 120-dBA stimulus was achieved through prepulses of distinct intensities (71, 77, and 83 dBA, which corresponded to 6, 12, and 18 dBA above background, respectively). (a) The figure shows percentage PPI (%PPI) as a function of prepulse intensity for CON offspring and offspring born to PolyI:C-treated mothers; in addition, the mean %PPI is depicted for all experimental groups. Prenatal PolyI:C exposure significantly reduced %PPI in vehicle (VEH)-treated animals compared with prenatal CON treatment. The prenatal PolyI:C-induced PPI disruption was normalized by periadolescent clozapine (CLZ) or fluoxetine (FLX) treatment but not by periadolescent haloperidol (HAL) treatment. The latter drug significantly reduced %PPI in adulthood when given to periadolescent offspring born to CON mothers. *P < .05, **P < .01, and ***P < .001, based on Fisher post hoc tests. (b) The figure depicts startle reactivity to prepulse-alone trials as a function of prepulse intensity. Periadolescent CLZ treatment increased the startle reactivity to prepulse-alone trials relative to VEH treatment during periadolescence. This effect was seen in both CON offspring and offspring born to PolyI:C-challenged mothers. HAL-treated PolyI:C offspring displayed a significant reduction in the startle reactivity to prepulse-alone trials relative to periadolescent VEH treatment in PolyI:C offspring. #P < .05 between VEH-treated CON or PolyI:C offspring and CLZ-treated CON or PolyI:C offspring; §P < .05 between HAL-treated PolyI:C offspring and VEH-treated PolyI:C offspring. Significance is based on Fisher post hoc tests at each of the 3 prepulse levels. (c) The figure shows the mean startle reactivity to the pulse-alone trials. Periadolescent FLX treatment significantly reduced the startle reactivity to the pulse-alone trials regardless of the prenatal treatment histories. +P < .05 between FLX- and VEH-treated animals based on subsequent Fisher post hoc tests. The number of subjects in each group is listed in table 1. All values are means ± standard error of the mean.